| Total axSpA (N = 278) | Non-drinker (N = 72) | Alcohol drinker (N = 206) | P |
---|---|---|---|---|
Age (years) | 39.0 ± 11.1 | 39.8 ± 13.4 | 38.7 ± 10.3 | 0.516 |
Diagnosed age (years) | 31.4 ± 11.5 | 32.9 ± 13.3 | 30.8 ± 10.7 | 0.227 |
Disease duration (years) | 7.5 ± 6.2 | 6.8 ± 5.8 | 7.7 ± 6.3 | 0.292 |
Follow-up duration (months) | 24.03 ± 1.55 | 24.11 ± 1.59 | 24.01 ± 1.54 | 0.601 |
Male (%) | 214 (77.0%) | 48 (66.7%) | 166 (80.6%) | 0.024 |
BMI (kg/m2) | 24.0 ± 3.2 | 23.9 ± 3.5 | 24.0 ± 3.1 | 0.856 |
Obesity (BMI ≥ 25 kg/m2) | 95 (34.2%) | 23 (31.9%) | 72 (35.0%) | 0.750 |
BMI ≥ 30 kg/m2 | 9 (3.2%) | 2 (2.8%) | 7 (3.4%) | 1.000 |
Current smoker (%) | 75 (27.1%) | 11 (15.3%) | 64 (31.2%) | 0.014 |
Alcohol consumption (unit/week) |  |  | 12.6 ± 15.0 |  |
Uveitis history (%) | 125 (45.5%) | 42 (59.2%) | 83 (40.7%) | 0.011 |
IBD history (%) | 3 (1.1%) | 1 (1.4%) | 2 (1.0%) | 1.000 |
Dactylitis history (%) | 21 (7.6%) | 6 (8.5%) | 15 (7.4%) | 0.968 |
Psoriasis history (%) | 15 (5.5%) | 3 (4.2%) | 12 (5.9%) | 0.821 |
BASDAI (0–10) | 2.9 ± 1.9 | 3.1 ± 1.9 | 2.9 ± 1.9 | 0.281 |
ASDAS-ESR (0–10) | 1.9 ± 0.9 | 2.0 ± 0.9 | 1.9 ± 0.9 | 0.274 |
ASDAS-CRP (0–10) | 1.8 ± 0.8 | 1.8 ± 0.8 | 1.8 ± 0.9 | 0.668 |
BASFI (0–10) | 0.8 ± 1.2 | 1.0 ± 1.4 | 0.8 ± 1.2 | 0.400 |
PGA (0–10) | 3.1 ± 2.2 | 3.3 ± 2.5 | 3.1 ± 2.1 | 0.570 |
Pain VAS (0–10) | 2.8 ± 2.4 | 3.3 ± 2.5 | 2.7 ± 2.3 | 0.092 |
PhyGA (0–10) | 2.4 ± 1.7 | 2.5 ± 1.9 | 2.3 ± 1.6 | 0.352 |
Peripheral arthritis (%) | 21 (7.7%) | 6 (8.7%) | 15 (7.4%) | 0.928 |
SPARCC Enthesitis index (0–16) | 0.2 ± 0.7 | 0.2 ± 0.7 | 0.2 ± 0.8 | 0.569 |
EQ-5D-5L-TTO | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.074 |
EQ-VAS (0–100) | 72.8 ± 17.6 | 71.7 ± 17.9 | 73.3 ± 17.5 | 0.510 |
ASAS health index (HI, 0–17) | 3.3 ± 3.0 | 4.1 ± 3.6 | 3.0 ± 2.8 | 0.019 |
Environmental factor related to ASAS HI (0–9) | 2.0 ± 1.5 | 2.3 ± 1.6 | 1.9 ± 1.4 | 0.058 |
Positive HLA-B27 (%) | 248 (93.9%) | 65 (95.6%) | 183 (93.4%) | 0.714 |
AS (satisfying mNY criteria, %) | 199 (71.6%) | 50 (69.4%) | 149 (72.3%) | 0.752 |
Mean grade of sacroiliitis | 2.4 ± 1.1 | 2.3 ± 1.0 | 2.5 ± 1.1 | 0.217 |
Baseline mSASSS (0–72) | 11.6 ± 16.1 | 11.2 ± 15.3 | 11.7 ± 16.4 | 0.796 |
Baseline syndemophyte count (0–24) | 4.0 ± 5.7 | 3.8 ± 5.3 | 4.1 ± 5.9 | 0.717 |
mSASSS change for 2 years | 2.4 ± 3.4 | 1.5 ± 2.8 | 2.7 ± 3.6 | 0.007 |
Syndemophyte change for 2 years | 0.7 ± 1.3 | 0.4 ± 1.2 | 0.9 ± 1.3 | 0.003 |
Current medication | ||||
 NSAID (%) | 197 (70.9%) | 53 (73.6%) | 144 (69.9%) | 0.656 |
 ASAS NSAID index (0–100) | 39.5 ± 36.1 | 40.9 ± 36.8 | 39.0 ± 35.9 | 0.702 |
 TNF-α inhibitor (%) | 146 (52.5%) | 40 (55.6%) | 106 (51.5%) | 0.644 |
 Sulfasalazine (%) | 85 (30.6%) | 17 (23.6%) | 68 (33.0%) | 0.180 |
 Methotrexate (%) | 6 (2.2%) | 2 (2.8%) | 4 (1.9%) | 1.000 |
 Bisphosphonate (%) | 23 (8.3%) | 7 (9.7%) | 16 (7.8%) | 0.787 |
 Vitamin D (%) | 88 (31.7%) | 26 (36.1%) | 62 (30.1%) | 0.425 |